Athira Pharma, Inc. (NASDAQ:LONA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:LONA) saw a significant decrease in short interest in September. As of September 15th, there was short interest totaling 23,651 shares, a decrease of 41.3% from the August 31st total of 40,293 shares. Based on an average trading volume of 64,689 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.3% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Citizens Jmp cut their price target on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Finally, Mizuho lowered their price objective on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, August 19th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Commodore Capital LP acquired a new stake in Athira Pharma in the fourth quarter valued at approximately $3,515,000. Spruce Street Capital LP bought a new stake in Athira Pharma during the 4th quarter valued at $2,980,000. Finally, Seven Fleet Capital Management LP acquired a new position in Athira Pharma during the fourth quarter worth $969,000. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Stock Performance

Shares of NASDAQ LONA traded up $0.13 during trading hours on Friday, reaching $4.51. 215,913 shares of the stock were exchanged, compared to its average volume of 94,842. The firm has a market capitalization of $42.38 million, a price-to-earnings ratio of -1.07 and a beta of 2.12. The stock’s fifty day simple moving average is $6.99 and its 200 day simple moving average is $8.42. Athira Pharma has a 52 week low of $2.21 and a 52 week high of $14.21.

Athira Pharma (NASDAQ:LONA) last announced its earnings results on Friday, August 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). Research analysts predict that Athira Pharma will post -2.67 EPS for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc is a biotechnology company focused on developing regenerative medicines for diseases involving neurodegeneration and neurological decline. The company’s research is based on the hepatocyte growth factor (HGF) pathway, which it believes may support neuronal health, repair, and regeneration.

Athira’s lead investigational product is fosgonimeton (also known as ATH-1017), a small-molecule therapy designed to activate the HGF/MET system. The treatment has been studied for Alzheimer’s disease and other neurological conditions, although it remains investigational and has not been approved for commercial use.

Athira was founded in 2011 and is based in the United States.